MOTS-c Research Overview: Mitochondrial-Derived Peptide in Preclinical Studies

Published: March 2026

MOTS-c (Mitochondrial-Derived Peptide): Research Overview

Overview

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within a short open reading frame (sORF) embedded in the mitochondrial 12S ribosomal RNA gene (MT-RNR1). First characterized in 2015 by Lee, Yen, and Cohen at the University of Southern California, MOTS-c is classified as a mitochondrial-derived peptide (MDP) — a class of small bioactive peptides translated from previously unrecognized coding sequences within the mitochondrial genome. Its identification expanded the known mitochondrial genetic repertoire beyond structural and energetic functions and demonstrated that the mitochondrial genome encodes regulatory signaling molecules with systemic reach.

Unlike the vast majority of peptide hormones, which are encoded in nuclear DNA, MOTS-c is translated directly from mitochondrial genetic material. This origin positions it as a genuine mitochondrial hormone — a signaling molecule capable of communicating metabolic status from the mitochondria to peripheral tissues, and, as subsequent research demonstrated, to the nucleus itself. Its sequence (MRWQEMGYIFYPRKLR) is highly conserved across mammalian species, consistent with a functionally important regulatory role. MOTS-c circulates in human plasma, and endogenous levels have been shown to fluctuate with age, metabolic state, and acute exercise, suggesting it participates in the body’s ongoing monitoring and regulation of energy homeostasis.

Research into MOTS-c has expanded substantially since its initial characterization, with published investigations exploring its molecular signaling pathways, its relationship to age-associated physiological changes, and its measurable behavior in human and animal models of metabolic challenge. Studies have examined MOTS-c in contexts ranging from high-fat dietary models to exercise physiology to population-level genetics in exceptionally long-lived individuals. The body of preclinical and early translational literature positions MOTS-c as one of the more extensively characterized mitochondrial-derived peptides currently under active investigation.

Molecular Profile

Mechanism of Action

The primary intracellular mechanism associated with MOTS-c involves activation of AMP-activated protein kinase (AMPK), a master regulator of cellular energy sensing. Research published in Cell Metabolism in 2015 by Lee et al. demonstrated that MOTS-c inhibits the folate cycle and its coupled de novo purine biosynthesis pathway within skeletal muscle cells, resulting in the accumulation of the endogenous AMPK agonist AICAR (5-aminoimidazole-4-carboxamide ribonucleotide). Elevated intracellular AICAR concentrations then activate AMPK, triggering a cascade of downstream metabolic effects including enhanced glucose uptake, fatty acid oxidation, and mitochondrial biogenesis signaling. This pathway situates MOTS-c as an endogenous regulator of the same molecular axis targeted pharmacologically by metformin and exercise-mimetic compounds, though through a distinct upstream mechanism tied to one-carbon metabolism.

Beyond its cytoplasmic actions, a 2018 study published in Cell Metabolism (Lee et al., PMID 29983246) revealed that MOTS-c undergoes nuclear translocation in response to metabolic stress stimuli including glucose restriction, serum deprivation, and oxidative stress. Within the nucleus, MOTS-c interacts with stress-responsive transcription factors — including NRF2 (nuclear factor erythroid 2-related factor 2) — and modulates genes containing antioxidant response elements (ARE). This nuclear translocation is AMPK-dependent: inhibition of AMPK suppressed MOTS-c nuclear entry. Cells overexpressing wild-type MOTS-c were protected against metabolic stress-induced injury, while nuclear translocation-deficient MOTS-c mutants conferred no such protection, directly implicating nuclear activity as mechanistically necessary.

MOTS-c’s signaling architecture also involves cross-talk with the NAD⁺/SIRT1 axis. Preclinical data indicate that MOTS-c administration is associated with increased NAD⁺ levels, and that SIRT1 — a NAD⁺-dependent deacetylase with established roles in metabolic adaptation and longevity biology — is partially involved in mediating MOTS-c’s downstream actions. This positions MOTS-c within an interconnected network of metabolic stress sensors, linking mitochondrial output to nuclear transcription, AMPK signaling, and NAD⁺-dependent epigenetic regulation. Whether these interactions are sequential or operate in parallel remains an active area of investigation in the published literature.

Key Areas of Investigation

Metabolic Homeostasis and Insulin Signaling in Cell and Animal Models

The foundational characterization of MOTS-c by Lee et al. (2015) in Cell Metabolism demonstrated that exogenous MOTS-c administration in murine models prevented both diet-induced obesity and high-fat diet-induced insulin resistance. In vitro studies using skeletal muscle cell lines showed that MOTS-c treatment enhanced glucose uptake in an AMPK-dependent manner and reduced lipid accumulation. A 2019 study by Kim, Miller, Mehta, and colleagues published in Physiological Reports (PMID 31293078) extended this framework by profiling plasma metabolite changes associated with MOTS-c administration in aged and diet-induced obese mouse models. MOTS-c-treated animals exhibited lower fasting glucose and insulin levels relative to controls, with metabolomics analysis revealing reductions across lipid-related metabolic pathways — suggesting systemic rather than purely local mechanisms.

Age-Associated Changes in Circulating MOTS-c Levels

Circulating MOTS-c concentrations have been investigated as a potential biological marker of aging. Preclinical studies have observed that endogenous MOTS-c levels in both skeletal muscle tissue and peripheral blood decline with age in rodent models, correlating temporally with the progressive development of age-associated insulin resistance. In human cross-sectional analyses, a clinical study by Cataldo et al. published in the Journal of Investigative Medicine (2018, PMID 29593067) examined plasma MOTS-c in lean versus obese participants and found that in lean individuals, plasma MOTS-c levels correlated positively with insulin sensitivity — while this association was absent in obese individuals, raising the possibility that obesity-related metabolic dysregulation may disrupt the MOTS-c signaling axis. These human observational data complement the preclinical intervention literature but do not establish causality.

Exercise Physiology and Skeletal Muscle Homeostasis

MOTS-c has been investigated as an exercise-induced mitochondrial signal. A 2021 study by Reynolds, Lai, Woodhead, and colleagues published in Nature Communications (PMID 33473109) demonstrated that acute exercise induces MOTS-c expression in skeletal muscle and elevates circulating plasma MOTS-c levels in humans, with concentrations rising approximately 50% during and immediately after exercise before returning to baseline during recovery. In aged mouse models, late-life-initiated intermittent MOTS-c treatment significantly improved physical performance, with older treated animals demonstrating approximately double the running capacity of untreated age-matched controls. These preclinical findings position MOTS-c as a molecular mediator of exercise-induced metabolic adaptation.

A review by Lee, Kim, and Cohen published in Free Radical Biology and Medicine (2016, PMID 27216708) discussed MOTS-c’s dual roles in skeletal muscle and adipose tissue — noting that depending on the metabolic context, MOTS-c may function both as a promoter of anabolic processes and as a lipolytic signal, consistent with its role as a sensor and responder to cellular energetic state.

Genetics, Polymorphisms, and Longevity Associations

The MT-RNR1 locus encoding MOTS-c is subject to natural genetic variation. Fuku and colleagues published research (PMID 26289118, Aging Cell, 2015) examining the mitochondrial polymorphism m.1382A>C, which falls within the MOTS-c-encoding open reading frame and alters its amino acid sequence. This variant is found at notably higher frequency in Northeast Asian centenarians, particularly in Japanese populations with documented exceptional longevity, than in younger comparison cohorts. The authors proposed that altered MOTS-c signaling resulting from this polymorphism may contribute to the metabolic resilience observed in long-lived individuals. Subsequent work has confirmed that different MOTS-c sequence variants exhibit differential activity in metabolic assays, consistent with functional consequences of naturally occurring sequence changes.

Nuclear Stress Response and Cytoprotection

The 2018 discovery that MOTS-c translocates to the nucleus under conditions of metabolic stress (Lee et al., PMID 29983246) opened a distinct line of investigation into MOTS-c’s role in cellular stress responses beyond metabolic regulation. In cell-based models, MOTS-c nuclear entry was observed within 30 minutes of glucose restriction or oxidative stress induction. Once in the nucleus, MOTS-c modulated a broad transcriptional program encompassing antioxidant response genes, consistent with interactions with NRF2 and other stress-responsive transcription factors. These cell-based findings have led investigators to examine MOTS-c in the context of oxidative stress, cellular senescence, and stress adaptation, though this body of work remains primarily preclinical in scope.

Key Published References

1. Lee C, Zeng J, Drew BG, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism. 2015;21(3):443–454. PMID: 25738459
2. Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biology and Medicine. 2016;100:182–187. PMID: 27216708
3. Lee C, Fan W, Lane M, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism. 2018;28(3):516–524. PMID: 29983246
4. Kim SJ, Miller B, Mehta HH, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports. 2019;7(13):e14171. PMID: 31293078
5. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1):470. PMID: 33473109
6. Cataldo LR, Fernández-Verdejo R, Santos JL, Galgani JE. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. Journal of Investigative Medicine. 2018;66(6):1019–1022. PMID: 29593067
7. Fuku N, Pareja-Galeano H, Zempo H, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell. 2015;14(6):921–923. PMID: 26289118

Product Availability

MOTS-c (10 mg) is available for qualified research applications through White Market Peptides: MOTS-c 10 mg — Research Grade.